Ischemia

Elucid Names Scott Huennekens Executive Chairman of the Board

Retrieved on: 
Tuesday, April 25, 2023
Health, Medical Devices, Technology, Hospitals, Radiology, Artificial Intelligence, Cardiology, IPO, University, Harvard University, Stroke, Marie Cassidy, Cardiovascular disease, MBA, Sale, J&J, Death, Ischemia, Patient, Physician, Risk, Vascular disease, Growth, Johnson & Johnson, FDA, Management, Medical imaging, Elucid, Wolfgang Hünnekens

Elucid, Inc ., a leading medical technology company providing physicians with AI-powered imaging analysis software to assess cardiovascular disease, today announced that it has named Scott Huennekens executive chairman of its board of directors.

Key Points: 
  • Elucid, Inc ., a leading medical technology company providing physicians with AI-powered imaging analysis software to assess cardiovascular disease, today announced that it has named Scott Huennekens executive chairman of its board of directors.
  • He has a proven track record in building innovative companies addressing large, unmet clinical needs,” said Elucid CEO Blake Richards.
  • “It is an honor to join Elucid as chairman of the board of directors,” said Huennekens.
  • Elucid is also pursuing an indication for FFRCT, uniquely derived from its PlaqueIQ technology, to non-invasively measure coronary blockages and the extent of ischemia.

Humacyte Announces Publication of Preclinical Study Comparing Human Acellular Vessel™ (HAV™) to Expanded Polytetrafluoroethylene (ePTFE) Graft in Vascular Trauma

Retrieved on: 
Tuesday, April 18, 2023
Infection, Biologics license application, Failure, Amputation, AC 25.1309-1, Aneurysm, Iliac artery, Reperfusion injury, Sale, Military personnel, Incidence, Polytetrafluoroethylene, Ischemia, Journal, Animal, Patient, HUMA, Host, Peripheral artery disease, FDA, HAV, Death, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, BLA, Food, Pharmaceutical industry, Medical imaging, Trauma

DURHAM, N.C., April 18, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, announced the publication of a preclinical study in the Journal of Trauma and Acute Care Surgery comparing the use of its Human Acellular Vessel (HAV) to expanded polytetrafluorethylene (ePTFE) grafts for vascular repair following arterial trauma. In the preclinical study the HAV performed better than ePTFE on multiple indices.

Key Points: 
  • In the preclinical study the HAV performed better than ePTFE on multiple indices.
  • In this comparative preclinical study, 36 pigs were randomly assigned to treatment groups receiving either the HAV or an ePTFE graft to reconstruct a severed iliac artery after vascular trauma.
  • At the conclusion of the study, the HAV and ePTFE implants were removed and histologically evaluated for host cellular response.
  • The publication of this preclinical study comes as Humacyte nears the completion of enrollment in its Phase 2/3 V005 clinical trial of the HAV in the repair of vascular trauma.

Genetesis Receives 2nd FDA Breakthrough Device Designation for Non-Invasive Diagnosis of Myocardial Ischemia Using CardioFlux MCG

Retrieved on: 
Thursday, April 13, 2023
Technology, Medical Devices, General Health, Hospitals, Science, Clinical Trials, FDA, Cardiology, Biotechnology, Health, Health Technology, Research, Other Technology, Audio, Video, Biometrics, Other Health, Radiology, MCG, Partnership, CMD, Dipyridamole, Hospital, Anatomy, Moyamoya disease, Principal investigator, Perception, Cardiovascular disease, European Society of Cardiology, Disease, History, Ischemia, Medical director, The Christ Hospital, Patient, Investment, Christ Hospital, Diagnosis, Education, European Society for Medical Oncology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Breakthrough, Interventional cardiology, Food, Pharmaceutical industry, Medical device

Genetesis, Inc., the leader in biomagnetic cardiac imaging solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted the company Breakthrough Device designation for its flagship imaging solution, CardioFlux MCG, to identify myocardial ischemia in patients who may be suffering from coronary microvascular disease (CMD).

Key Points: 
  • Genetesis, Inc., the leader in biomagnetic cardiac imaging solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted the company Breakthrough Device designation for its flagship imaging solution, CardioFlux MCG, to identify myocardial ischemia in patients who may be suffering from coronary microvascular disease (CMD).
  • Annually, as many as 4 million patients in the United States alone are believed to present with diagnostic evidence of ischemia without evidence of obstructed coronary arteries, a condition broadly known as INOCA.
  • The FDA’s decision rested, in part, on the submission of preliminary findings from the MICRO trial, which attempted to demonstrate the use of non-invasive magnetocardiography (MCG) to diagnose myocardial ischemia in patients suspected to be suffering from CMD.
  • “Through various activities and investments, like our Women’s Heart Center, we’re making very real progress on that goal.

Perfuse Therapeutics Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of PER-001 Intravitreal Implant in Patients with Glaucoma

Retrieved on: 
Wednesday, April 5, 2023
Retina, Glaucoma, IOP, US Foods, ARVO, Ranibizumab, Cell death, Clinical trial, Trigeminal ganglion, Inflammation, Ischemia, Investigational New Drug, MD, Patient, Vance DeGeneres, SAN, Diabetic retinopathy, FDA, Therapy, IND, Perfusion, Food, Safety, Pharmaceutical industry

SAN FRANCISCO, April 4, 2023 /PRNewswire/ -- Perfuse Therapeutics, a biopharmaceutical company pioneering transformational therapies to treat ischemia-induced ocular diseases announced today that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for a Phase 1/2a clinical study of PER-001 Intravitreal Implant in patients with glaucoma.

Key Points: 
  • The first-in human single-arm, open label, Phase 1 portion of the study will evaluate the safety and tolerability of PER-001 Intravitreal Implant in patients with advanced glaucoma.
  • The Phase 2a trial, is a patient masked, randomized, sham-controlled study that will evaluate the safety, tolerability, and pharmacodynamics of two doses of PER-001 in patients with progressing glaucoma.
  • "The initiation of this Ph1/2a clinical trial is a significant milestone for both Perfuse and the glaucoma community as we advance into the clinic with a novel, IOP-independent treatment for glaucoma" said Sevgi Gurkan, MD, CEO and Founder of Perfuse Therapeutics.
  • "We are excited to evaluate the PER-001 Intravitreal Implant in the Phase 1/2a trial."

Andrew Miller Joints Elucid as Chief Technology Officer

Retrieved on: 
Tuesday, March 28, 2023
Health, Medical Devices, Technology, Health Technology, Software, Artificial Intelligence, Cardiology, Software as a service, Workflow, Marie Cassidy, Cardiovascular disease, Oracle, Organization, Miller, Ischemia, Acquisition, Physician, Engineering, Outline of health sciences, FDA, Management, Elucid

Elucid, Inc. , a leading medical technology company providing physicians with AI-powered imaging analysis software to assess cardiovascular disease, has hired Andrew Miller as its chief technology officer (CTO).

Key Points: 
  • Elucid, Inc. , a leading medical technology company providing physicians with AI-powered imaging analysis software to assess cardiovascular disease, has hired Andrew Miller as its chief technology officer (CTO).
  • Elucid is also pursuing an indication for FFRCT, uniquely derived from its PlaqueIQ technology, to non-invasively measure coronary blockages and the extent of ischemia.
  • He has an incredible technological skillset and proven track record in building high-performing technology teams across numerous successful organizations throughout his career,” said Blake Richards, chief executive officer, Elucid.
  • Miller joins recent hires Dr. Todd Villines , chief medical officer, and Scott Burger , chief commercial officer, on Elucid’s leadership team.

Feinstein Institutes’ Study Discovers That Mitochondrial Transplantation Improves Survival and Outcomes After Cardiac Arrest

Retrieved on: 
Thursday, March 16, 2023
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Health, Hospitals, Clinical Trials, Multimedia, Transplant, Resuscitation, Teaching hospital, Dorothy, Medical research, Lance Becker, Brain, MTX, Survival, Feinstein Institutes for Medical Research, Credit, Cell, Oxygen, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Long Island Jewish Medical Center, Tissue, Food, Becker, Organelle, Animal, Mitochondrion, BMC Medicine, Emergency medicine, Cardiac arrest, Weingut Brüder Dr. Becker, Stroke, Northwell Health, Ischemia, Medical device, Dentistry, Medicine, MD

Through a series of studies, researchers at The Feinstein Institutes for Medical Research have shown that mitochondria transplantation (MTx), delivering new mitochondria to critical tissues, can improve survival and neurological outcomes after cardiac arrest.

Key Points: 
  • Through a series of studies, researchers at The Feinstein Institutes for Medical Research have shown that mitochondria transplantation (MTx), delivering new mitochondria to critical tissues, can improve survival and neurological outcomes after cardiac arrest.
  • View the full release here: https://www.businesswire.com/news/home/20230316005460/en/
    Dr. Lance Becker led the new research on mitochondria transplantation.
  • “Mitochondria transplantation is an untapped area of research and therapy that could lead to clinical benefits to restore much-needed energy.
  • The results showed that the animals receiving fresh mitochondria infusion improved neurological function and survival, from 55 percent to 91 percent, after cardiac arrest and resuscitation.

Diabetic Retinopathy Pipeline Research Report 2022: Featuring Insights on 60+ Companies and Drugs in the Sector - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 8, 2023
Pharmaceutical, Health, Optical, Route, Physician, Diabetic retinopathy, News, Edema, VEGF, Growth, Clinical trial, Fragment crystallizable region, Discovery, Injection, Administration, Anti-VEGF, AMD, NAV, Patient, Therapy, Ischemia, Drug development, Route of administration, Cerebral edema, GameChanger, Branch retinal vein occlusion, Pharmaceutical industry, Vaccine, Brolucizumab

Anti-VEGF agents have become a very common treatment to improve the clinical outcomes in patients with diabetic retinopathy.

Key Points: 
  • Anti-VEGF agents have become a very common treatment to improve the clinical outcomes in patients with diabetic retinopathy.
  • This segment of the report provides insights about the different Diabetic Retinopathy drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • The companies which have their Diabetic Retinopathy drug candidates in the mid to advanced stage, i.e.
  • Phase III include, Kodiak Sciences
    Diabetic Retinopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Palisade Bio Receives Intention to Grant from European Patent Office for LB1148 Patent

Retrieved on: 
Wednesday, March 1, 2023
Ileus, Ischemia, Sepsis, Patent, European Patent Office, Burns, Shock, Incidence, EPO, Nursing care plan, Trauma, Pharmaceutical industry, Palisade

In addition to this European patent, the Company continues to bolster its global intellectual property portfolio surrounding LB1148 with submitted and planned submissions of additional patent applications.

Key Points: 
  • In addition to this European patent, the Company continues to bolster its global intellectual property portfolio surrounding LB1148 with submitted and planned submissions of additional patent applications.
  • “We are pleased to receive this encouraging feedback from the EPO for our LB1148 patent and look forward to adding a granted patent to our growing IP portfolio.
  • Finley, interim Chief Executive Officer of Palisade Bio.
  • The patent application, with application number 19209258, for which the EPO has issued an Intention to Grant notice, relates to Palisade Bio’s proprietary compositions for oral administration.

Myocardial Infarction (MI) Market is Projected to Grow at a Minimal CAGR of 1.61% During the Study Period (2019-2032) | Assesses DelveInsight

Retrieved on: 
Thursday, January 26, 2023
Therapy, Phase, Vomiting, EU4, Amgen, CSL Behring, AstraZeneca, United Kingdom, Boehringer Ingelheim, Diagnosis, Pain, Idorsia, Novartis, Nausea, ACS, Human, Medicine, Neck, Ischemia, Sensation, Eli Lilly and Company, Chest pain, Pressure, Perspiration, Patient, Immediate, MI, ECG, Pharmaceutical industry, Bayer

LAS VEGAS, Jan. 26, 2023 /PRNewswire/ -- DelveInsight's MI Market Insights report includes a comprehensive understanding of current treatment practices, MI emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Key Points: 
  • With an estimated key regulatory submission acceptance after 2023
    MI is pathologically defined as myocardial cell death caused by prolonged ischemia.
  • Symptoms of MI include chest pain, which may initially manifest as a sensation of tightness or pressure.
  • DelveInsight estimates that there were approximately 15 million diagnosed prevalent cases of MI in the 7MM in 2021.
  • The MI market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Myocardial Infarction (MI) Market is Projected to Grow at a Minimal CAGR of 1.61% During the Study Period (2019-2032) | Assesses DelveInsight

Retrieved on: 
Thursday, January 26, 2023
Therapy, Phase, Vomiting, EU4, Amgen, CSL Behring, AstraZeneca, United Kingdom, Boehringer Ingelheim, Diagnosis, Pain, Idorsia, Novartis, Nausea, ACS, Human, Medicine, Neck, Ischemia, Sensation, Eli Lilly and Company, Chest pain, Pressure, Perspiration, Patient, Immediate, MI, ECG, Pharmaceutical industry, Bayer

LAS VEGAS, Jan. 26, 2023 /PRNewswire/ -- DelveInsight's MI Market Insights report includes a comprehensive understanding of current treatment practices, MI emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Key Points: 
  • With an estimated key regulatory submission acceptance after 2023
    MI is pathologically defined as myocardial cell death caused by prolonged ischemia.
  • Symptoms of MI include chest pain, which may initially manifest as a sensation of tightness or pressure.
  • DelveInsight estimates that there were approximately 15 million diagnosed prevalent cases of MI in the 7MM in 2021.
  • The MI market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into: